RABGGTA — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL10047259	1.00	9/20
SCHEMBL10047260	1.00	9/20
SCHEMBL10047265	1.00	9/20
SCHEMBL10073357	1.00	9/20
SCHEMBL10073361	1.00	9/20
SCHEMBL10073370	1.00	9/20
SCHEMBL10047253	0.85	9/20
SCHEMBL10073371	0.85	9/20
SCHEMBL10047245	0.84	9/20
SCHEMBL10072988	0.84	9/20
SCHEMBL14882801	0.84	9/20
SCHEMBL10047250	0.83	9/20
SCHEMBL10073599	0.83	9/20
SCHEMBL10047264	0.81	9/20
SCHEMBL10073606	0.81	9/20
SCHEMBL10047248	0.78	9/20
SCHEMBL10073812	0.78	9/20
SCHEMBL10047249	0.77	9/20
SCHEMBL10072993	0.77	9/20
SCHEMBL14882690	0.77	9/20

Clinical trials — most relevant to RABGGTA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS	PHASE3	RECRUITING
Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC	PHASE3	COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)	PHASE2	COMPLETED
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis	PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain	nan	RECRUITING
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
Study of Autoimmune Lymphoproliferative Syndrome (ALPS)	nan	RECRUITING
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia	nan	RECRUITING
United States Hypophosphatasia Molecular Research Center	nan	COMPLETED
Characteristics of Hypophosphatasia in Adult Patients in Rheumatology	nan	UNKNOWN
Genetic Mapping of Atherogenic Lipoprotein Phenotypes	nan	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Registry of Patients With Hypophosphatasia	nan	ENROLLING_BY_INVITATION
Serum Alkaline Phosphatase Levels In Healthy Turkish Children	nan	COMPLETED
Pediatric Evaluation and Registry for Liver Cholestasis in Canada	nan	RECRUITING
Checkpoint Inhibitor-induced Liver Injury	nan	RECRUITING
Effect Of Scaling and Root Planning on ALP in Saliva and GCF In Periodontitis Patients Compared With Healthy Individuals	nan	UNKNOWN
A Prospective Sub-Study of the Global Hypophosphatasia Registry	nan	RECRUITING
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Changes in the Hepatobiliary System in Patients With Primary Biliary Cholangitis Before and After Treatment.	nan	ACTIVE_NOT_RECRUITING
Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer	nan	COMPLETED
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)	nan	RECRUITING
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients	nan	RECRUITING
Biomarker for Hypophosphatasia Disease (BioHypophos)	nan	WITHDRAWN
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center Study	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a RABGGTA binder may also engage these)

Protein	Name	Similarity
Q5NVK5	—	1.000	Q5NVK5 →
Q5EA80	—	1.000	Q5EA80 →
A5A779	—	1.000	A5A779 →
Q9JHK4	—	1.000	Q9JHK4 →
Q08602	—	0.998	Q08602 →
P47823	—	0.976	P47823 →
EIF2B5	Translation initiation factor eIF2B subunit epsilon	0.975	landscape →
Q99LG4	—	0.974	Q99LG4 →
A5PK19	—	0.973	A5PK19 →
Q5BK48	—	0.972	Q5BK48 →
Q8N0Z6	—	0.972	Q8N0Z6 →
A7MB11	—	0.972	A7MB11 →
Q8CHW4	—	0.972	Q8CHW4 →
Q64350	—	0.971	Q64350 →
A4IG72	—	0.971	A4IG72 →
Q8N6R0	—	0.970	Q8N6R0 →
Q86Y56	—	0.970	Q86Y56 →
Q91YR5	—	0.970	Q91YR5 →
Q0P5H9	—	0.970	Q0P5H9 →
Q3UFQ8	—	0.969	Q3UFQ8 →
Q8MIR4	—	0.969	Q8MIR4 →
RNF31	E3 ubiquitin-protein ligase RNF31	0.969	landscape →
Q8BYR1	—	0.969	Q8BYR1 →
Q8ND23	—	0.968	Q8ND23 →
Q9BSK4	—	0.968	Q9BSK4 →
Q7TMC8	—	0.968	Q7TMC8 →
Q5EA11	—	0.968	Q5EA11 →
Q3UZW7	—	0.968	Q3UZW7 →
Q9UNS1	—	0.968	Q9UNS1 →
Q924T7	—	0.968	Q924T7 →